Ticagrelore Alone Post PCI

Official title

A Single-center, Randomized, 6-month, Non-inferiority Study to Compare the Safety and Efficacy of TICAgreLor mONotherapy Versus Dual Antiplatelet Therapy in Chronic Coronary Syndrome Patients Post Percutaneous Coronary IntErvention (TICALONE)

Overview

After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in registry of professor Kojuri cardiology clinic

Detailed description

An interventional cardiologist will perform angiography with the supervision of a fellow interventional cardiologist. Patients who need revascularization will undergo PCI using DES (Drug-eluting stent). PCI will be performed using the radial or femoral approach to achieve complete revascularization of at least one stenosis with a diameter of ≥50%. All target lesions will be revascularized using the 4th generation DES.

Randomization (1:1) will take place after diagnostic angiography but before stent insertion (figure 1). Eligible patients will be divided into two groups: the reference group, which will get conventional DAPT with aspirin and Clopidogrel (80 mg aspirin once daily, and 75mg clopidogrel once daily), and the experimental group, which will receive ticagrelor monotherapy (90mg twice daily) following PCI for six months.

Antiplatelet therapy will start before or at the time of PCI. Patients will receive a loading dose of assigned drugs (325mg for aspirin, 300mg for clopidogrel, and 180mg for ticagrelor) before stent insertion unless they are already on pre-PCI maintenance therapy with the mentioned drugs.

Subjects are randomly assigned a treatment strategy by an interactive web response system.

The primary efficacy endpoint is a composite of cardiac death, target vessel MI, stent thrombosis, and the need for revascularization occurring within 6 months of PCI. The secondary endpoints are all-cause death, occurrence of MACE including stroke (ischemic, hemorrhagic, or unknown), MI, arrhythmia, and each component of the primary endpoint at 6 months.

Safety is the third outcome

Interventions

• Drug aspirin 80 mg and clopidogrel 75 mg daily
  post PCI patients received these two drugs as dual antiplatelet regimen
• Drug Ticagrelor 90 MG
  Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet

Primary outcome measures

• stent thrombosis [Time frame: 6 months]
• Major adverse cardiovascular events [Time frame: 6 months]
• Bleeding [Time frame: 6 months]

Secondary outcome measures (1)

• Treatment related adverse reactions [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

• Male or female above 20 years of age undergoing PCI with a drug-eluting stent for chronic coronary syndrome
• The patient has provided written informed consent as approved by the ethics committee of the Shiraz University of Medical Sciences.

Exclusion criteria

• Contraindication to aspirin, clopidogrel, ticagrelor, or any other reason that study drug should not be administered (including hypersensitivity, moderate or severe liver disease, active bleeding, and major surgery within 30 days)
• Atrial fibrillation or other indication for oral anticoagulant therapy.
• Concomitant oral or IV therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices (cyclosporine, and quinidine), or strong CYP3A inducers ( rifampin, rifampicin, phenytoin, and carbamazepine)
• Females of child-bearing age unless negative pregnancy test at screening and willing to use effective contraception for the duration of trial
• Females who are breastfeeding at the time of enrolment.
• Unsuccessful PCI or PCI without optimal stent placement; this decision is made by the supervising interventional cardiologist.
• patients with anatomical SYNTAX score ≥23 prior to PCI
• Patients with planned surgical intervention to treat any cardiac or non-cardiac condition.
• Previous PCI in the last 6 months.
• Current (same hospitalization) or previous (within 12 months) acute coronary syndrome.
• History of definite stent thrombosis.
• Concomitant cardiac valve disease requiring invasive therapy.
• Acute heart failure.
• Active myocarditis.
• Cardiomyopathy.
• Patient in hemodialysis.
• History of stroke or transient ischemic cerebrovascular accident.
• History of intracranial hemorrhage or other intracranial pathology associated with increased bleeding risk.
• Hemoglobin <10 g/dL
• Peptic ulceration documented by endoscopy within the last 3 months unless healing proven by repeat endoscopy.
• Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with ticagrelor.
• Participation in another trial with an investigational drug or device.
• Assessment that the subject is not likely to comply with the study procedures or have complete follow-up.
• Known drug or alcohol dependence within the past 12 months as judged by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Treatment

Study locations

Iran · 2 centers

• Cardiology Ward Shiraz University of Medical Sciences — Shiraz
• professor Kojuroi cardiology clinic — Shiraz

Publications

• Mirhosseini SA, Akbari M, Aldavood D, Zarifkar H, Attar A, Kojuri J. Rationale and design of randomized non-inferiority clinical trial to compare the safety and efficacy of ticagrelor monotherapy with dual antiplatelet therapy in chronic coronary syndrome patients post percutaneous coronary intervention (TICALONE-TAHA10 Protocol). PLoS One. 2025 Jul 16;20(7):e0325663. doi: 10.1371/journal.pone.032 PMID 40668853

Identifiers

NCT: NCT06509893 · IR.SUMS.MED.REC.1403.150

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗